Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

Postgraduate Medicine

Volumn 127, Issue 5, 2015, Pages 494-502

  Behary, Preeshila ^a   Cegla, Jaimini ^a   Tan, Tricia M ^a   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bariatric surgery; Drugs; Gut hormones; Lifestyle management; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; ALBIGLUTIDE; AMFEBUTAMONE PLUS NALTREXONE; DIPEPTIDYL PEPTIDASE IV; DULAGLUTIDE; EXENDIN 4; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; LIXISENATIDE; MELANOCORTIN; NEUROPEPTIDE; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; GASTROINTESTINAL HORMONE;

BODY MASS; DIET RESTRICTION; DRUG THERAPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTRIC BANDING; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION; BARIATRIC SURGERY; LIFESTYLE; PHYSIOLOGY;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; GASTROINTESTINAL HORMONES; HUMANS; LIFE STYLE; OBESITY;

EID: 84964053766     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2015.1048181     Document Type: Review

References (122)

1. WHO. Report of the advisory committee on health research. Geneva: Genomics and World Health; 2002.
2. Tunstall- Pedoe H, Tunstall-Pedoe H. Preventing chronic diseases. A Vital investment: WHO global report. World Health Organization, Geneva; 2005. pp 200. Available from http://www.who.int/chp/chronic_disease_report/en/. Int J Epidemiol 2006;35(4):1107.
3. Vasant H. Adult anthropometric measures, overweight and obesity. In Health Survey for England. Volume 1. Adult anthropometric measures, overweight and obesity In Health Survey for England. Health Social Care Heath Centre 2010.
4. Bridges ST. Children’s BMI, overweight and obesity. Health Survey Engl 2010.
5. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491–7.
6. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483–90.
7. Fried M, Yumuk V, Oppert JM, Scopinaro N, Torres A, Weiner R, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg 2014;24:42–55.
8. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378:804–14.
9. Johansson K, Sundström J, Marcus C, Hemmingsson E, Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obesity 2014;38:279–84.
10. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity 2006;14:1283–93.
11. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Human Nutr Diet 2004;17:317–35.
12. Malik VS, Hu FB. Popular weight-loss diets: from evidence to practice. Nat Clin Pract Cardiov Med 2007;4:34–41.
13. Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of Low-Carbohydrate and Low-Fat Diets. Ann Int Med 2014;161:309.
14. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Eng J Med 2009;360:859–73.
15. Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA 2014;312:923.
16. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–6.
17. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506–14.
18. Damms-Machado A, Weser G, Bischoff SC. Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J 2012;11:34.
19. Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obesity 2005;29:1168–74.
20. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obesity 2005;29:1153–67.
21. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43–53.
22. Keys A. Human starvation and its consequences. J Am Diet Assoc 1946;22:582–7.
23. Lomer M. Advanced Nutrition and dietetics in Gastroenterology. Wiley Blackwell, West Sussex, UK; 2014.
24. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Eng J Med 2011;365: 1597–604.
25. Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, Ludwig DS. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012;307:2627–34.
26. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Eng J Med 1995;332:621–8.
27. Camps SG, Verhoef SP, Westerterp KR. Weight loss, weight maintenance, and adaptive thermogenesis 1-3. Am J Clin Nutr 2013;97:990–5.
28. Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav 2013;120:106–13.
29. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Investig 2008; 118:2583–91.
30. Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One 2013;8:e59114.
31. Catenacci VA, Wyatt HR. The role of physical activity in producing and maintaining weight loss. Nat Clin Pract Endocrinol Metabol 2007;3:518–29.
32. Tate DF, Jeffery RW, Sherwood NE, Wing RR. Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain? Am J Clin Nutr 2007;85:954–9.
33. NICE guidelines [CG189]. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults 1-recommendations Guidance and guidelines. 2014.
34. Physical Activity Guidelines for Americans. 2008. Available from: http://www.health.gov/paguidelines/guidelines/chapter4. aspx.
35. Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults’ participation in physical activity: review and update. Med Sci Sports Exercise 2002;34:1996–2001.
36. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol 2014;63:2985–3023.
37. Kayman S, Bruvold W, Stern JS. Maintenance and relapse after weight loss in women: behavioral aspects. Am J Clin Nutr 1990;52:800–7.
38. WHO. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. WHO Technical. World Health Organization, Geneva; 2000. Available from http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/.
39. NIH conference. Gastrointestinal surgery for severe obesity. consensus development conference panel. Ann Int Med 1991;115:956–61.
40. Busetto L, Dixon J, De Luca M, Shikora S, Pories W, Angrisani L. Bariatric surgery in class I obesity: a position statement from the international federation for the surgery of obesity and metabolic disorders (IFSO). Obes Surg 2014;24:487–519.
41. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N. Bariatric Surgery Worldwide 2013. Obesity Surgery 2015. [Epub ahead of print].
42. Slater GH, Ren CJ, Siegel N, Williams T, Barr D, Wolfe B, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastroint Surg 2004;8:48–55; discussion 54–5.
43. Aasheim ET, Bjo S, Hanvold SE, Engström M, Hanvold SE, Mala T, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch 1 – 3. Am J Clin Nutr 2009;90:15–22.
44. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56.
45. Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 2012;99:100–3.
46. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Eng J Med 2012;366:1577–85.
47. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–34.
48. Trastulli S, Desiderio J, Guarino S, Frampton GK. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surgery Obesity Related Dis 2013;9:816–29.
49. Wang MC, Guo XH, Zhang YW, Zhang YL, Zhang HH, Zhang YC. Laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy for obese patients with Type 2 diabetes: a meta-analysis of randomized controlled trials. Am Surg 2015;81:166–71.
50. Diamantis T, Apostolou KG, Alexandrou A, Frampton GK. Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surgery Obesity Related Dis 2014;10:177–83.
51. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Eng J Med 2014;370:2002–13.
52. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Jacobsen SH, Hansen DL, Worm D, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012;55:1890–901.
53. Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Sur Obesity Relat Dis 2005;1:358–68.
54. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after dietinduced weight loss or gastric bypass surgery. N Eng J Med 2002;346:1623–30.
55. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210–15.
56. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780–5.
57. Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108–14.
58. Näslund E, Backman L, Holst JJ, Theodorsson E, Hellström PM. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obesity Surg 1998;8:253–60.
59. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51:S434–42.
60. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, et al. A meta-analysis of the effect of glucagonlike peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382–9.
61. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696–701.
62. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Eng J Med 2003;349:941–8.
63. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obesity 2006;30:1729–36.
64. Fenske WK, Bueter M, Miras a D, Ghatei MA, Bloom SR, le Roux CW. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obesity 2012;36: 379–84.
65. Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: Role of gut peptides. J Clin Endoc Metab 2011;96:2227–35.
66. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obesity 2013;37:1452–9.
67. Jime_nez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013;36:2062–9.
68. Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 2014;3:191–201.
69. Jørgensen NB, Dirksen C, Bojsen-møller KN, Jacobsen SH, Worm D, Hansen DL, et al. Exaggerated glucagon-like peptide 1 response is important for improved b-cell function and glucose tolerance after roux-en-y gastric bypass in patients with type 2 diabetes. 2014;62:3044–52.
70. Gribble FM. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc 2012;71:456–62.
71. Hao Z, Townsend RL, Mumphrey MB, Patterson LM, Ye J, Berthoud HR. Vagal innervation of intestine contributes to weight loss After Roux-en-Y gastric bypass surgery in rats. Obesity Surg 2014;24:2145–51.
72. Gautron L, Zechner JF, Aguirre V. Vagal innervation patterns following Roux-en-Y gastric bypass in the mouse. Int J Obesity 2013;37:1603–7.
73. Le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 2005;90:4521–4.
74. Werling M, Vincent RP, Cross GF, Marschall HU, Fändriks L, Lönroth H, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 2013;48:1257–64.
75. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obesity Surg 2012;22:740–8.
76. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012;153:3613–19.
77. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, et al. Metabolic surgery profoundly influences gut microbialhost metabolic cross-talk. Gut 2011;60:1214–23.
78. Liou AP, Paziuk M, Luevano JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41.
79. Sweeney TE, Morton JM. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol 2014;28:727–40.
80. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479–85.
81. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obesity 2009;33:786–95.
82. Olbers T, Björkman S, Lindroos A, Maleckas A, Lönn L, Sjöström L, Lönroth H. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006;244:715–22.
83. Scholtz S, Miras AD, Chhina N, Prechtl CG, Sleeth ML, Daud NM, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut 2014;63:891–902.
84. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and metaanalysis. Surgery 2007;142:621–32.
85. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabetic Med 2011;28:628–42.
86. Jackson TD, Zhang R, Glockler D, Pennington J, Reddigan JI, Rotstein OD, et al. Health inequity in access to bariatric surgery: a protocol for a systematic review. System Rev 2014;3:15.
87. Ahmad A, Laverty AA, Aasheim E, Majeed A, Millett C, Saxena S. Eligibility for bariatric surgery among adults in England: analysis of a national cross-sectional survey. JRSM open 2014;5:2042533313512479.
88. European Medicines Agency. Draft Guideline on clinical evaluation of medicinal products used in weight control. 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170278.pdf.
89. Colman E. Food and drug administration’s obesity drug guidance document: a short history. Circulation 2012;125:2156–64.
90. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Eng J Med 2010;363:905–17.
91. Samat A, Tomlinson B, Taheri S, Thomas GN. Rimonabant for the treatment of obesity. Recent Patents Cardiov Drug Discov 2008;3:187–93.
92. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Int Med 2005;142:532–46.
93. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61.
94. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N Eng J Med 2012;367:1577–9.
95. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Eng J Med 2010;363:245–56.
96. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52.
97. Press Announcements. FDA approves weight-management drug Saxenda [Internet]. 2015. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm.
98. Press Announcements. FDA approves weight-management drug Contrave [Internet]. 2014. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm.
99. European Medicines Agency. News and Events - Saxenda recommended for approval in weight management in adults [Internet]. 2015. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002255.jsp&mid=WC0b01ac058004d5c1.
100. Ornellas T, Chavez B. Naltrexone SR/Bupropion SR (Contrave): A new approach to weight loss in obese adults. P T 2011;36:255–62.
101. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (CORI): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605.
102. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013;21:935–43.
103. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type2 diabetes. Diabetes Care 2013;36:4022–9.
104. Meeran K, O’Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999;140:244–50.
105. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72.
106. Parker JA, McCullough KA, Field BC, Minnion JS, Martin NM, Ghatei MA, Bloom SR. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obesity 2013;37:1391–8.
107. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19–28.
108. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47.
109. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obesity 2013;37:1443–51.
110. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–16.
111. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obesity 2012;36:843–54.
112. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin- treated patients with type 2 diabetes mellitus. Diabetes 2006;8:419–28.
113. Elashoff M, Matveyenko A V, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–6.
114. Nauck MA. A critical analysis of the clinical use of incretinbased therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126–32.
115. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36:S245–52.
116. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124:1325–36.
117. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989–92.
118. Tan TM, Field BCT, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012;73:232–9.
119. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–4.
120. Tan TM, Field BCT, McCullough KA, Troke RC, Chambers ES, Salem V, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013;62:1131–8.
121. Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957;11:419–21.
122. Fosgerau K, Hoffmann T. Peptide therapeutics: Current status and future directions. Drug Discov Today 2015;20:122–8.